New molecular causes of brain cancer and leukemia have been revealed by new research. An enzyme that is responsible for the breakdown of specific amino acids in food plays a key role in the development of leukemias and brain cancer.
Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have reported the findings in Nature. The researchers have hence discovered a surprising link between energy metabolism and the so-called epigenetic code. These labels in the DNA of cancer stem cells determine the activity of genes and, thus, many cellular functions. The authors think that blocking this enzyme is a promising possibility to combat cancer.
New Biomarker Indicates Progression of Brain Cancer
New biomarker identified aids in indicating the progression and drug response in glioblastoma tumors (brain cancer) and can lead to new diagnostics and therapies.
Advertisement
‘Misregulated methylation with its drastic consequences for the whole cell appears to be a common characteristic of acute myeloid leukemia.’
Tweet it Now
Acute myeloid leukemia (AML) is an aggressive type of blood cancer that very often relapses in the wake of successful initial treatment. Stem cells that are resistant to therapy are held responsible for this. Scientists working with Andreas Trumpp from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and HI-STEM wanted to understand the molecular background to this resistance. To this end, they examined patient samples by comparing the composition of proteins of AML stem cells and leukemia cells without stem cells properties.
The investigators found suspiciously high levels of an enzyme called BCAT1 in the stem cells. These levels rose even higher during a cancer recurrence. The researchers considered this to be a clue that BCAT1 might be linked to therapy resistance.
![Genes Linked to Bladder and Brain Cancer Identified]( "Genes Linked to Bladder and Brain Cancer Identified")
A particular gene fusion has a worsening effect on cancer cells.Preventing cell 'signaling' from this particular fusion may not be an effective way for future cancer treatment
Cancer researchers have suspected for some time that the BCAT1 enzyme, which is responsible for the breakdown of specific proteins in food, plays a role in the development of malignant tumors. A team led by Bernhard Radlwimmer from DKFZ had recently found that an overproduction of BCAT1 increases the aggressiveness of malignant brain tumors and breast cancer.
The two research groups have now joined forces in order to find out how BCAT1 influences the therapy resistance of leukemia stem cells. They discovered a previously unknown process in which a key molecule of energy metabolism plays a crucial role. BCAT1 reduces the levels of this key molecule and this leads to increased levels of chemical labels in the DNA.
"These tiny methyl groups that are attached to DNA determine whether particular genes are active or silent and, thus, have an immense impact on all cellular functions", said Simon Raffel, one of the study's first authors.
This result made the two DKFZ teams pay close attention, because in another 30 percent of AML cases, defects in other enzymes lead to the same consequence: They increase cancer-promoting methylation of DNA. AML is known for an extremely heterogeneous pattern of genetic alterations. However, misregulated methylation with its drastic consequences for the whole cell appears to be a common characteristic of this malignant disease.
The finding that BCAT1 drives cancer-promoting methylation in AML stem cells and other cancer stem cells opens up new options for therapy: "A blockade of the enzyme using a targeted agent might normalize DNA methylation and thereby reduce cancer spread and therapy resistance"; Trumpp said.
Source: Eurekalert
Genes Linked to Bladder and Brain Cancer Identified
A particular gene fusion has a worsening effect on cancer cells.Preventing cell 'signaling' from this particular fusion may not be an effective way for future cancer treatment
Advertisement
Cancer researchers have suspected for some time that the BCAT1 enzyme, which is responsible for the breakdown of specific proteins in food, plays a role in the development of malignant tumors. A team led by Bernhard Radlwimmer from DKFZ had recently found that an overproduction of BCAT1 increases the aggressiveness of malignant brain tumors and breast cancer.
The two research groups have now joined forces in order to find out how BCAT1 influences the therapy resistance of leukemia stem cells. They discovered a previously unknown process in which a key molecule of energy metabolism plays a crucial role. BCAT1 reduces the levels of this key molecule and this leads to increased levels of chemical labels in the DNA.
"These tiny methyl groups that are attached to DNA determine whether particular genes are active or silent and, thus, have an immense impact on all cellular functions", said Simon Raffel, one of the study's first authors.
This result made the two DKFZ teams pay close attention, because in another 30 percent of AML cases, defects in other enzymes lead to the same consequence: They increase cancer-promoting methylation of DNA. AML is known for an extremely heterogeneous pattern of genetic alterations. However, misregulated methylation with its drastic consequences for the whole cell appears to be a common characteristic of this malignant disease.
The finding that BCAT1 drives cancer-promoting methylation in AML stem cells and other cancer stem cells opens up new options for therapy: "A blockade of the enzyme using a targeted agent might normalize DNA methylation and thereby reduce cancer spread and therapy resistance"; Trumpp said.
Source: Eurekalert
New Genetic Variation Identified in Childhood Brain Cancer
About 500 medulloblastomas have been examined by the researchers, as medulloblastoma, a malignant tumor of the cerebellum occurs commonly in children.
Advertisement
CD44s A Survival Advantage to Brain CancerUnderstanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Located at the South Col, the rocky area between Mount Everest and Lhotse serves as the final campsite for climbers as well as a frozen legacy of hardy microbes.
The new finding is found to be valuable for screening specific medications and treatment against Giardia and other protozoan parasites.
New CRISPR genome-editing strategy was found to have a positive impact in the treatment of inherited retinal diseases such as retinitis pigmentosa.
H3N2 Influenza: The newly developed RT-qPCR Kit to identify influenza, COVID-19 and respiratory virus has got approval from ICMR.
Does hormone replacement therapy help rheumatoid arthritis? Yes, the use of exogenous sex hormones is associated with remission in perimenopausal female patients.